You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Last Updated: September 22, 2023

Investigational Drug Information for GDC-0917


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for GDC-0917?

GDC-0917 is an investigational drug.

There have been 189 clinical trials for GDC-0917. The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are seven US patents protecting this investigational drug and one hundred and ninety international patents.

Recent Clinical Trials for GDC-0917
TitleSponsorPhase
Preoperative Window of Opportunity Study With Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women With ER[+]/HER2[-] & Ki67≥10% Early Breast CancerMedSIRPhase 2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of GDC-6036 in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationHoffmann-La RochePhase 1/Phase 2
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic CoughGenentech, Inc.Phase 1/Phase 2

See all GDC-0917 clinical trials

Clinical Trial Summary for GDC-0917

Top disease conditions for GDC-0917
Top clinical trial sponsors for GDC-0917

See all GDC-0917 clinical trials

US Patents for GDC-0917

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0917 ⤷  Try a Trial Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB) ⤷  Try a Trial
GDC-0917 ⤷  Try a Trial Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (Cambridge, GB) CANCER RESEARCH TECHNOLOGY LIMITED (London, GB) ⤷  Try a Trial
GDC-0917 ⤷  Try a Trial Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (New Haven, CT) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Baxter
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.